Alban Ordureau

This study identifies RPL22L1 as a BAG6-RNF115 substrate whose degradation is regulated by its assembly state into the ribosome, revealing a mechanism linking protein quality control to ribosome biogenesis.

The paper uses isogenic cortical organoids to identify variant-specific pathogenic pathways in Alzheimer's disease and demonstrates targeted interventions that restore neuronal survival.

The paper shows hypoxia-induced mitochondrial ROS leads to M1 ubiquitin chains, activating NF-κB signaling and increasing target gene expression in response to mitochondrial stress.

This study uses chemical probes to assess HMGCS1 inhibition, showing similar proteome effects to HMGCR inhibition and demonstrating efficacy in statin-resistant models.

The paper uses ER stressors in ALS patient-derived motor neurons to identify druggable targets that protect against degeneration.

This study shows that impaired lysosomal proteolysis in astrocytes leads to proteostasis failure in midbrain neurons in an early-onset PD model.

This study identifies MTK458, a PINK1 activator, which reduces α-synuclein pathology and pUb levels in Parkinson's disease models and correlates plasma pUb with disease progression.

The paper uses proteomics to compare autophagy cargos in two Parkinson disease mouse models, finding distinct adaptive pathways in PINK1 and LRRK2 models.